ATMP (Advanced Therapy Medicinal Products) facilities are different to the more conventional pharmaceutical facilities, often requiring heightened segregation. Many organizations are evaluating how different modalities may be combined within the same facility having acquired a building, or having constructed an agnostic building. Accommodating multiple modalities in the same facility is therefore becoming an increasingly important requirement and not least during the COVID-19 pandemic when rapidly developing and launching new vaccines. The presentation describes a basic framework and methodology that may be used when evaluating different types of modalities and how they may be accommodated in a new or existing facility. A case study is used to demonstrate how the approach may be applied to an existing facility.
Biopharma & Advanced Therapies SME,